A significant proportion of patients who suffer from atrial fibrillation (AF) and are in need of thromboembolic protection are not treated with oral anticoagulation or discontinue this treatment shortly after its initiation. This undertreatment has not improved sufficiently despite the availability of direct oral anticoagulants which are associated with less major bleeding than vitamin K antagonists. Multiple reasons account for this, including bleeding events or ischaemic strokes whilst on anticoagulation, a serious risk of bleeding events, poor treatment compliance despite best educational attempts, or aversion to drug therapy. An alternative interventional therapy, which is not associated with long-term bleeding and is as effective as vitamin K anticoagulation, was introduced over 20 years ago. Because of significant improvements in procedural safety over the years, left atrial appendage closure, predominantly achieved using a catheter-based, device implantation approach, is increasingly favoured for the prevention of thromboembolic events in patients who cannot achieve effective anticoagulation. This management strategy is well known to the interventional cardiologist/electrophysiologist but is not more widely appreciated within cardiology or internal medicine. This article introduces the devices and briefly explains the implantation technique. The indications and device follow-up are more comprehensively described. Almost all physicians who care for adult patients will have many with AF. This practical guide, written within guideline/guidance boundaries, is aimed at those non-implanting physicians who may need to refer patients for consideration of this new therapy, which is becoming increasingly popular.

1st Department of Cardiology Poznan University School of Medical Sciences Poznan Poland

Berlin Institute of Health Center for Regenerative Therapies Berlin Germany

Cardioangiologisches Centrum Bethanien Agaplesion Markus Krankenhaus Frankfurt Germany

Cardioangiology Center Bethanien CCB Frankfurt Germany

Cardiologie Clinique Pasteur Brussels University VUB Brussels Belgium

Cardiology Department St Antonius Hospital Nieuwegein Amsterdam University Medical Centers Amsterdam Netherlands

Cardiology Division Department of Biomedical Metabolic and Neural Sciences University of Modena and Reggio Emilia Policlinico di Modena Modena Italy

Cardiology Heart Rhythm Management Department Clinique Pasteur Toulouse France

Cardiovascular Center Aalst OLV Hospital Aalst Belgium

Center for Vascular Research Munich Germany

Centro Cardiologico Monzino IRCCS Department of Clinical Electrophysiology and Cardiac Pacing Department of Biomedical Surgical and Dental Sciences University of Milan Milan Italy

Danish Center for Health Services Research Department of Clinical Medicine Aalborg University Aalborg Denmark

Department of Cardiology Aarhus University Hospital Aarhus Denmark

Department of Cardiology Angiology and Intensive Care Medicine Deutsches Herzzentrum Charité Charité University Medicine Berlin

Department of Cardiology University Heart and Vascular Centre Hamburg Hamburg Germany

Department of Cardiology University Hospital Kralovske Vinohrady Charles University Prague Czech Republic

Department of Neurology Universitätsklinikum Würzburg Würzburg Germany

Department of Surgery Oncology and Gastroenterology University Hospital of Padua Padua Italy

Deutsches Herzzentrum der Charité Campus Virchow Klinikum Berlin Germany

Division of Cardiology European Georges Pompidou Hospital AP HP Paris France

Division of Nephrology Miull General Hospital Acquaviva delle Fonti Italy

EuDial Working Group of the European Renal Association Acquaviva delle Fonti Italy

Genetic and Cardiovascular Sciences Institute Cardiology Academic Group St George's University of London Cranmer Terrace London SW190RE UK

German Centre for Cardiovascular Research partner site Berlin Charité Universitätsmedizin Berlin Germany

German Centre for Cardiovascular Research Partner Site Hamburg Kiel Lübeck Hamburg Germany

German Heart Center Charite Campus Mitte Berlin Germany

Ippokrateio Hospital of Thessaloniki Aristotle University of Thessaloniki Thessaloniki Greece

Istituto Auxologico Italiano IRCCS Milan Italy

Leicester NIHR BRU University of Leicester Glenfield Hospital Leicester UK

Liverpool Centre for Cardiovascular Science at University of Liverpool Liverpool John Moores University and Liverpool Heart and Chest Hospital Liverpool UK

Medical Faculty University of Belgrade Belgrade Serbia

Nephrology and Dialysis Unit ASL Toscana NordOvest Livorno Italy

Ospedale del Cuore Fondazione CNR Regione Toscana G Monasterio Pisa Italy

School of Medicine and Surgery University of Milano Bicocca Nephrology Clinic Monza Italy

Structural and Congenital Heart Disease European Interbalkan Medical Centre Thessaloniki Greece

University Clinical Centre of Serbia Belgrade Serbia

Erratum v

Europace. 2024 May 2;26(5):euae142. doi: 10.1093/europace/euae142 PubMed

Zobrazit více v PubMed

Benjamin  EJ, Muntner  P, Alonso  A, Bittencourt  MS, Callaway  CW, Carson  AP, et al.  Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation  2019;139:e56–28. PubMed

Krijthe  BP, Kunst  A, Benjamin  EJ, Lip  GY, Franco  OH, Hofman  A, et al.  Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J  2013;34:2746–51. PubMed PMC

Hart  RG, Pearce  LA, Aguilar  MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med  2007;146:857–67. PubMed

Ruff  CT, Giugliano  RP, Braunwald  E, Hoffman  EB, Deenadayalu  N, Ezekowitz  MD, et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet  2014;383:955–62. PubMed

Ray  WA, Chung  CP, Stein  CM, Smalley  W, Zimmerman  E, Dupont  WD, et al.  Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA  2021;326:2395–404. PubMed PMC

Hedner  U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost  2006;32:77–85. PubMed

Marijon  E, Le Heuzey  JY, Connolly  S, Yang  S, Pogue  J, Brueckmann  M, et al.  Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation  2013;128:2192–201. PubMed

Carnicelli  AP, Hong  H, Connolly  SJ, Eikelboom  J, Giugliano  RP, Morrow  DA, et al.  Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation  2022;145:242–55. PubMed PMC

Little  D, Chai-Adisaksopha  C, Hillis  C, Witt  DM, Monreal  M, Crowther  MA, et al.  Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: a systematic review and meta-analysis. Thromb Res  2019;175:102–9. PubMed

Karim  N, Ho  SY, Nicol  E, Li  W, Zemrak  F, Markides  V, et al.  The left atrial appendage in humans: structure, physiology, and pathogenesis. Europace  2020;22:5–18. PubMed

Reddy  VY, Doshi  SK, Kar  S, Gibson  DN, Price  MJ, Huber  K, et al.  5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol  2017;70:2964–75. PubMed

Osmancik  P, Herman  D, Neuzil  P, Hala  P, Taborsky  M, Kala  P, et al.  4-Year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation. J Am Coll Cardiol  2022;79:1–14. PubMed

Turagam  MK, Osmancik  P, Neuzil  P, Dukkipati  SR, Reddy  VY. Left atrial appendage closure versus oral anticoagulants in atrial fibrillation: a meta-analysis of randomized trials. J Am Coll Cardiol  2020;76:2795–7. PubMed

Turagam  MK, Kawamura  I, Neuzil  P, Nair  D, Doshi  S, Valderrabano  M, et al.  Severity of ischemic stroke after left atrial appendage closure vs nonwarfarin oral anticoagulants. JACC Clin Electrophysiol  2023. doi:10.1016/j.jacep.2023.10.012. Epub ahead of print. PubMed DOI

Tzikas  A, Shakir  S, Gafoor  S, Omran  H, Berti  S, Santoro  G, et al.  Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER cardiac plug. EuroIntervention  2016;11:1170–9. PubMed

Hildick-Smith  D, Landmesser  U, Camm  AJ, Diener  HC, Paul  V, Schmidt  B, et al.  Left atrial appendage occlusion with the Amplatzer Amulet device: full results of the prospective global observational study. Eur Heart J  2020;41:2894–901. PubMed PMC

Boersma  LV, Ince  H, Kische  S, Pokushalov  E, Schmitz  T, Schmidt  B, et al.  Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial. Heart Rhythm  2017;14:1302–8. PubMed

Freeman  JV, Varosy  P, Price  MJ, Slotwiner  D, Kusumoto  FM, Rammohan  C, et al.  The NCDR left atrial appendage occlusion registry. J Am Coll Cardiol  2020;75:1503–18. PubMed PMC

Price  MJ, Slotwiner  D, Du  C, Freeman  JV, Turi  Z, Rammohan  C, et al.  Clinical outcomes at 1 year following transcatheter left atrial appendage occlusion in the United States. JACC Cardiovasc Interv  2022;15:741–50. PubMed PMC

Doshi  SK, Kar  S, Sadhu  A, Horton  R, Osorio  J, Ellis  C, et al.  Two-year outcomes with a next-generation left atrial appendage device: final results of the PINNACLE FLX trial. J Am Heart Assoc  2023;12:e026295. PubMed PMC

Waranugraha  Y, Lin  LY, Tsai  CT. Head-to-head comparison between left atrial appendage occlusion and non-vitamin K oral anticoagulants in non-valvular atrial fibrillation patients: a systematic review and meta-analysis study. Trends Cardiovasc Med  2023. doi:10.1016/j.tcm.2023.02.002. Epub ahead of print. PubMed DOI

Whitlock  RP, Belley-Cote  EP, Paparella  D, Healey  JS, Brady  K, Sharma  M, et al.  Left atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med  2021;384:2081–91. PubMed

Bayer . A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke. 2022. https://classic.clinicaltrials.gov/show/NCT05643573 (8 February 2024, date last accessed).

Anthos Therapeutics Inc., The TIMI Study Group, Laboratory Corporation of America . Safety and tolerability of abelacimab (MAA868) vs. rivaroxaban in patients with atrial fibrillation. 2021. https://classic.clinicaltrials.gov/show/NCT04755283 (8 February 2024, date last accessed).

Anthos Therapeutics Inc . Study to evaLuate the effIcacy and aafety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC-TIMI 76). 2022. https://classic.clinicaltrials.gov/show/NCT05712200 (8 February 2024, date last accessed).

Janssen Research Development LLC, Bristol-Myers Squibb . A study of Milvexian versus apixaban in participants with atrial fibrillation. 2023. https://classic.clinicaltrials.gov/show/NCT05757869 (8 February 2024, date last accessed).

Boston Scientific Corporation . Assessment of the WATCHMAN™ device in patients unsuitable for oral anticoagulation. 2017. https://classic.clinicaltrials.gov/show/NCT02928497 (8 February 2024, date last accessed).

Charite University Berlin Germany, Deutsches Zentrum für Herz-Kreislauf-Forschung, Atrial Fibrillation Network, Stiftung Institut fuer Herzinfarktforschung . Left atrial appendage CLOSURE in patients with atrial fibrillation compared to medical therapy. 2018. https://classic.clinicaltrials.gov/show/NCT03463317 (8 February 2024, date last accessed).

Karolinska Institutet, Abbott Medical Devices . Prevention of stroke by left atrial appendage closure in atrial fibrillation patients after intracerebral hemorrhage. 2017. https://classic.clinicaltrials.gov/show/NCT02830152 (8 February 2024, date last accessed).

Jena University Hospital . Comparison of LAA-closure vs oral anticoagulation in patients with NVAF and status post intracranial bleeding. 2020. https://classic.clinicaltrials.gov/show/NCT04298723 (8 February 2024, date last accessed).

Huijboom  M, Maarse  M, Aarnink  E, van Dijk  V, Swaans  M, van der Heijden  J, et al.  COMPARE LAAO: rationale and design of the randomized controlled trial “Comparing effectiveness and safety of left atrial appendage occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagulation therapy”. Am Heart J  2022;250:45–56. PubMed

R&D Cardiologie, Research ZTNOfH, Development . Left atrial appendage occlusion for AF patients unable to use oral anticoagulation therapy. 2021. https://classic.clinicaltrials.gov/show/NCT04676880 (8 February 2024, date last accessed).

Eitel  I. Left atrial appendage closure in patients with non-valvular atrial fibrillation and end-stage chronic KIDNEY disease. 2022. https://classic.clinicaltrials.gov/show/NCT05204212 (8 February 2024, date last accessed).

Wazni  OM, Boersma  L, Healey  JS, Mansour  M, Tondo  C, Phillips  K, et al.  Comparison of anticoagulation with left atrial appendage closure after atrial fibrillation ablation: rationale and design of the OPTION randomized trial. Am Heart J  2022;251:35–42. PubMed

Boston Scientific Corporation . Comparison of anticoagulation with left atrial appendage closure after AF ablation. 2019. https://classic.clinicaltrials.gov/show/NCT03795298 (8 February 2024, last date accessed).

Kar  S, Doshi  SK, Alkhouli  M, Camm  AJ, Coylewright  M, Gibson  MC, et al.  Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation. Am Heart J  2023;264:123–32. PubMed

Abbott Medical Devices . Amplatzer Amulet LAAO vs. NOAC. 2020. https://classic.clinicaltrials.gov/show/NCT04226547 (8 February 2024, date last accessed).

University of Aarhus Aarhus University Hospital Aalborg University Hospital Odense University Hospital Sahlgrenska University Hospital Sweden Karolinska University Hospital, et al. Left atrial appendage occlusion versus novel oral anticoagulation for stroke prevention in atrial fibrillation. 2019. https://classic.clinicaltrials.gov/show/NCT03642509 (8 February 2024, date last accessed).

Korsholm  K, Damgaard  D, Valentin  JB, Packer  EJS, Odenstedt  J, Sinisalo  J, et al.  Left atrial appendage occlusion vs novel oral anticoagulation for stroke prevention in atrial fibrillation: rationale and design of the multicenter randomized occlusion-AF trial. Am Heart J  2022;243:28–38. PubMed

Nielsen-Kudsk  JE, Johnsen  SP, Wester  P, Damgaard  D, Airaksinen  J, Lund  J, et al.  Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study. EuroIntervention  2017;13:371–8. PubMed

Nielsen-Kudsk  JE, Korsholm  K, Damgaard  D, Valentin  JB, Diener  HC, Camm  AJ, et al.  Clinical outcomes associated with left atrial appendage occlusion versus direct oral anticoagulation in atrial fibrillation. JACC Cardiovasc Interv  2021;14:69–78. PubMed

Lip  GYH, Proietti  M, Potpara  T, Mansour  M, Savelieva  I, Tse  HF, et al.  Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal. Europace  2023;25:euad226. PubMed PMC

Romiti  GF, Pastori  D, Rivera-Caravaca  JM, Ding  WY, Gue  YX, Menichelli  D, et al.  Adherence to the ‘atrial fibrillation better care’ pathway in patients with atrial fibrillation: impact on clinical outcomes-A systematic review and meta-analysis of 285,000 patients. Thromb Haemost  2022;122:406–14. PubMed

Patel  SM, Palazzolo  MG, Murphy  SA, Antman  EM, Braunwald  E, Lanz  HJ, et al.  Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial. Europace  2022;24:1730–8. PubMed

Proietti  M, Romiti  GF, Olshansky  B, Lane  DA, Lip  GYH. Comprehensive management with the ABC (atrial fibrillation better care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM trial. J Am Heart Assoc  2020;9:e014932. PubMed PMC

Shrestha  B, Poudel  B, Poudel  D, Diaz Fraga  J. National yearly trend of utilization and procedural complication of the watchman device in the United States. Cureus  2022;14:e25567. PubMed PMC

Boriani  G, Proietti  M, Laroche  C, Fauchier  L, Marin  F, Nabauer  M, et al.  Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF general long-term registry. Europace  2019;21:1013–22. PubMed

Potpara  TS, Dan  GA, Trendafilova  E, Goda  A, Kusljugic  Z, Manola  S, et al.  Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan region: the BALKAN-AF survey. Sci Rep  2016;6:20432. PubMed PMC

Juhl Madsen  O, Lamberts  MK, Fosboel  EL, Gislason  G, Olesen  JB, Strange  JE. Trends in percutaneous left atrial appendage occlusion and 1-year mortality: a nationwide cohort study. Eur Heart J  2022;43:ehac544.2137.

Lip  GYH, Banerjee  A, Boriani  G, Chiang  CE, Fargo  R, Freedman  B, et al.  Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest  2018;154:1121–201. PubMed

NHFA CSANZ Atrial Fibrillation Guideline Working Group, Brieger  D, Amerena  J, Attia  J, Bajorek  B, Chan  KH, et al.  National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Heart Lung Circ  2018;27:1209–66. PubMed

Hindricks  G, Potpara  T, Dagres  N, Arbelo  E, Bax  JJ, Blomström-Lundqvist  C, et al.  2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J  2021;42:373–498. PubMed

Andrade  JG, Aguilar  M, Atzema  C, Bell  A, Cairns  JA, Cheung  CC, et al.  The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive guidelines for the management of atrial fibrillation. Can J Cardiol  2020;36:1847–948. PubMed

Chao  TF, Joung  B, Takahashi  Y, Lim  TW, Choi  EK, Chan  YH, et al.  2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost  2022;122:20–47. PubMed PMC

Saw  J, Holmes  DR, Cavalcante  JL, Freeman  JV, Goldsweig  AM, Kavinsky  CJ, et al.  SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. JACC Cardiovasc Interv  2023;16:1384–400. PubMed

Joglar  JA, Chung  MK, Armbruster  AL, Benjamin  EJ, Chyou  JY, Cronin  EM, et al.  2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation  2023;149:e1–156. PubMed PMC

Glikson  M, Wolff  R, Hindricks  G, Mandrola  J, Camm  AJ, Lip  GYH, et al.  EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion—an update. EuroIntervention  2020;15:1133–80. PubMed

Tzikas  A, Holmes  DR  Jr, Gafoor  S, Ruiz  CE, Blomström-Lundqvist  C, Diener  HC, et al.  Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace  2017;19:4–15. PubMed PMC

January  CT, Wann  LS, Calkins  H, Chen  LY, Cigarroa  JE, Cleveland  JC  Jr, et al.  2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol  2019;74:104–32. PubMed

Anic  A, Bakovic  D, Jurisic  Z, Farkowski  M, Lisica  L, Breskovic  T, et al.  Diagnostic and therapeutic pathways for the malignant left atrial appendage: European Heart Rhythm Association physician survey. Europace  2023;25:euad204. PubMed PMC

Camm  AJ. Leap or lag: left atrial appendage closure and guidelines. Europace  2023;25:euad067. PubMed PMC

Glikson  M, Wolff  R, Hindricks  G, Mandrola  J, Camm  AJ, Lip  GYH, et al.  EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion—an update. Europace  2020;22:184. PubMed

National Institute for Health and Clinical Excellence . Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism: NICE guidance. Heart  2010;97:762–5. PubMed

Di Biase  L, Briceno  DF, Trivedi  C, Mohanty  S, Gianni  C, Burkhardt  JD, et al.  Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry. Heart Rhythm  2016;13:1197–202. PubMed

Lee  OH, Kim  JS, Pak  HN, Hong  GR, Shim  CY, Uhm  JS, et al.  Feasibility of left atrial appendage occlusion for left atrial appendage thrombus in patients with persistent atrial fibrillation. Am J Cardiol  2018;121:1534–9. PubMed

Korsholm  K, Berti  S, Iriart  X, Saw  J, Wang  DD, Cochet  H, et al.  Expert recommendations on cardiac computed tomography for planning transcatheter left atrial appendage occlusion. JACC Cardiovasc Interv  2020;13:277–92. PubMed

Osmancik  P, Herman  D, Linkova  H, Hozman  M, Labos  M. A comparison of cardiac computed tomography, transesophageal and intracardiac echocardiography, and fluoroscopy for planning left atrial appendage closure. J Atr Fibrillation  2021;13:20200449. PubMed PMC

Sharma  PS, Padala  SK, Gunda  S, Koneru  JN, Ellenbogen  KA. Vascular complications during catheter ablation of cardiac arrhythmias: a comparison between vascular ultrasound guided access and conventional vascular access. J Cardiovasc Electrophysiol  2016;27:1160–6. PubMed

Yamagata  K, Wichterle  D, Roubíček  T, Jarkovský  P, Sato  Y, Kogure  T, et al.  Ultrasound-guided versus conventional femoral venipuncture for catheter ablation of atrial fibrillation: a multicentre randomized efficacy and safety trial (ULTRA-FAST trial). Europace  2018;20:1107–14. PubMed

Sobolev  M, Shiloh  AL, Di Biase  L, Slovut  DP. Ultrasound-guided cannulation of the femoral vein in electrophysiological procedures: a systematic review and meta-analysis. Europace  2017;19:850–5. PubMed

Brass  P, Hellmich  M, Kolodziej  L, Schick  G, Smith  AF. Ultrasound guidance versus anatomical landmarks for subclavian or femoral vein catheterization. Cochrane Database Syst Rev  2015;1:CD011447. PubMed PMC

Kupó  P, Pap  R, Sághy  L, Tényi  D, Bálint  A, Debreceni  D, et al.  Ultrasound guidance for femoral venous access in electrophysiology procedures—systematic review and meta-analysis. J Interv Card Electrophysiol  2020;59:407–14. PubMed PMC

Delgado  V, Ajmone Marsan  N, de Waha  S, Bonaros  N, Brida  M, Burri  H, et al.  2023 ESC guidelines for the management of endocarditis. Eur Heart J  2023;44:3948–4042. PubMed

Vizzari  G, Grasso  C, Sardone  A, Mazzone  P, Laterra  G, Frazzetto  M, et al.  Real-world experience with the new Watchman FLX device: data from two high-volume sicilian centers. The FLX-iEST registry. Catheter Cardiovasc Interv  2022;100:154–60. PubMed

Price  MJ, Friedman  DJ, Du  C, Wang  Y, Lin  Z, Curtis  JP, et al.  Comparative safety of transcatheter LAAO with the first-generation Watchman and next-generation Watchman FLX devices. JACC Cardiovasc Interv  2022;15:2115–23. PubMed

Paitazoglou  C, Meincke  F, Bergmann  MW, Eitel  I, Fink  T, Vireca  E, et al.  The ALSTER-FLX Registry: 3-month outcomes after left atrial appendage occlusion using a next-generation device, a matched-pair analysis to EWOLUTION. Heart Rhythm  2022;19:917–26. PubMed

Lakkireddy  D, Thaler  D, Ellis  CR, Swarup  V, Sondergaard  L, Carroll  J, et al.  Outcomes of the roll-in cohort of the Amulet IDE trial of left atrial appendage occlusion. Heart Rhythm O2  2022;3:493–500. PubMed PMC

Chen  S, Chun  KRJ, Bordignon  S, Weise  FK, Nagase  T, Perrotta  L, et al.  Left atrial appendage occlusion using LAmbre Amulet and Watchman in atrial fibrillation. J Cardiol  2019;73:299–306. PubMed

Tilz  RR, Fink  T, Bartus  K, Wong  T, Vogler  J, Nentwich  K, et al.  A collective European experience with left atrial appendage suture ligation using the LARIAT+ device. Europace  2020;22:924–31. PubMed

Betts  TR, Grygier  M, Nielsen Kudsk  JE, Schmitz  T, Sandri  M, Casu  G, et al.  Real-world clinical outcomes with a next-generation left atrial appendage closure device: the FLXibility post-approval study. Europace  2023;25:914–21. PubMed PMC

Bhogal  S, Aladin  AI, Wermers  JP, Morrison  N, Gray  N, Waksman  R. Review of late-breaking trials from CRT 2022. Cardiovasc Revasc Med  2022;40S:3–7. PubMed PMC

Merdler  I, Reddy  PK, Bhogal  S, Wermers  JP, Salimes  BG, Gray  N, et al.  Review of late-breaking trials from CRT 2023. Cardiovasc Revasc Med  2023;53:S3–9. PubMed

Lakkireddy  D, Thaler  D, Ellis  CR, Swarup  V, Sondergaard  L, Carroll  J, et al.  Amplatzer Amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial. Circulation  2021;144:1543–52. PubMed PMC

Messele  LF, Khan  MZ, Darden  D, Agarwal  S, Krishan  S, Pasupula  DK, et al.  Outcomes of percutaneous left atrial appendage occlusion device implantation in atrial fibrillation patients based on underlying stroke risk. Europace  2023;25:1415–22. PubMed PMC

Holmes  DR, Reddy  VY, Turi  ZG, Doshi  SK, Sievert  H, Buchbinder  M, et al.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet  2009;374:534–42. PubMed

Reddy  VY, Doshi  SK, Sievert  H, Buchbinder  M, Neuzil  P, Huber  K, et al.  Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial. Circulation  2013;127:720–9. PubMed

Bergmann  MW, Betts  TR, Sievert  H, Schmidt  B, Pokushalov  E, Kische  S, et al.  Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry. EuroIntervention  2017;13:877–84. PubMed

Berti  S, Pastormerlo  LE, Rezzaghi  M, Trianni  G, Paradossi  U, Cerone  E, et al.  Left atrial appendage occlusion in high-risk patients with non-valvular atrial fibrillation. Heart  2016;102:1969–73. PubMed

Korsholm  K, Nielsen  KM, Jensen  JM, Jensen  HK, Andersen  G, Nielsen-Kudsk  JE. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy. EuroIntervention  2017;12:2075–82. PubMed

Landmesser  U, Schmidt  B, Nielsen-Kudsk  JE, Lam  SCC, Park  JW, Tarantini  G  et al.  Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention  2017;13:867–76. PubMed

Saw  J, Tzikas  A, Shakir  S, Gafoor  S, Omran  H, Nielsen-Kudsk  JE, et al.  Incidence and clinical impact of device-associated thrombus and peri-device leak following left atrial appendage closure with the amplatzer cardiac plug. JACC Cardiovasc Interv  2017;10:391–9. PubMed

Kar  S, Doshi  SK, Sadhu  A, Horton  R, Osorio  J, Ellis  C, et al.  Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial. Circulation  2021;143:1754–62. PubMed

Ellis  CR, Jackson  GG, Kanagasundram  AN, Mansour  M, Sutton  B, Houle  VM, et al.  Left atrial appendage closure in patients with prohibitive anatomy: insights from PINNACLE FLX. Heart Rhythm  2021;18:1153–61. PubMed

Korsholm  K, Samaras  A, Andersen  A, Jensen  JM, Nielsen-Kudsk  JE. The Watchman FLX device: first European experience and feasibility of intracardiac echocardiography to guide implantation. JACC Clin Electrophysiol  2020;6:1633–42. PubMed

Paitazoglou  C, Bergmann  MW, Ince  H, Kische  S, Romanov  A, Schmitz  T, et al.  True efficacy of LAA closure: patient outcomes on long-term single-antiplatelet or no therapy: insights from the EWOLUTION registry. J Invasive Cardiol  2022;34:E348–55. PubMed

Simard  T, Jung  RG, Lehenbauer  K, Piayda  K, Pracoń  R, Jackson  GG, et al.  Predictors of device-related thrombus following percutaneous left atrial appendage occlusion. J Am Coll Cardiol  2021;78:297–313. PubMed

Cepas-Guillén  P, Flores-Umanzor  E, Leduc  N, Bajoras  V, Perrin  N, Farjat-Pasos  J, et al.  Impact of device implant depth after left atrial appendage occlusion. JACC Cardiovasc Interv  2023;16:2139–49. PubMed

Saliba  WI, Kawai  K, Sato  Y, Kopesky  E, Cheng  Q, Ghosh  SKB, et al.  Enhanced thromboresistance and endothelialization of a novel fluoropolymer-coated left atrial appendage closure device. JACC Clin Electrophysiol  2023;9:1555–67. PubMed

Lakkireddy  D, Nielsen-Kudsk  JE, Windecker  S, Thaler  D, Price  MJ, Gambhir  A, et al.  Mechanisms, predictors, and evolution of severe peri-device leaks with two different left atrial appendage occluders. Europace  2023;25:euad237. PubMed PMC

Della Rocca  DG, Murtaza  G, Di Biase  L, Akella  K, Krishnan  SC, Magnocavallo  M, et al.  Radiofrequency energy applications targeting significant residual leaks after watchman implantation: a prospective, multicenter experience. JACC Clin Electrophysiol  2021;7:1573–84. PubMed

Sievert  H, Lesh  MD, Trepels  T, Omran  H, Bartorelli  A, Della Bella  P, et al.  Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation  2002;105:1887–9. PubMed

Gorgis  S, Dabbagh  MF, Mishra  K, Ahluwalia  G, Hana  A, Fram  G, et al.  Unprotected discharge: absence of stroke prevention strategies in patients with atrial fibrillation admitted for bleeding. J Interv Card Electrophysiol  2021;62:337–46. PubMed

Proietti  M, Romiti  GF, Romanazzi  I, Farcomeni  A, Staerk  L, Nielsen  PB, et al.  Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol  2018;261:84–91. PubMed

Sengupta  N, Feuerstein  JD, Patwardhan  VR, Tapper  EB, Ketwaroo  GA, Thaker  AM, et al.  The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. Am J Gastroenterol  2015;110:328–35. PubMed

Staerk  L, Lip  GY, Olesen  JB, Fosbøl  EL, Pallisgaard  JL, Bonde  AN, et al.  Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ  2015;351:h5876. PubMed PMC

Deitelzweig  S, Keshishian  A, Kang  A, Dhamane  AD, Luo  X, Balachander  N, et al.  Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients. Therap Adv Gastroenterol  2021;14:1756284821997352. PubMed PMC

Ahn  HJ, Lee  SR, Choi  EK, Rhee  TM, Kwon  S, Oh  S, et al.  Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: a systematic review and meta-analysis. Br J Clin Pharmacol  2022;88:4676–87. PubMed

Sanz Segura  P, Jimeno Sánchez  J, Arbonés-Mainar  JM, Sánchez-Rubio Lezcano  J, Galache Osuna  G, Bernal Monterde  V. Percutaneous left atrial appendage closure in patients with gastrointestinal bleeding associated with oral anticoagulants. Scand J Gastroenterol  2023;58:1547–54. PubMed

Boersma  LV, Schmidt  B, Betts  TR, Sievert  H, Tamburino  C, Teiger  E, et al.  Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J  2016;37:2465–74. PubMed PMC

Qureshi  W, Mittal  C, Patsias  I, Garikapati  K, Kuchipudi  A, Cheema  G, et al.  Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol  2014;113:662–8. PubMed

Lempereur  M, Aminian  A, Freixa  X, Gafoor  S, Shakir  S, Omran  H, et al.  Left atrial appendage occlusion in patients with atrial fibrillation and previous major gastrointestinal bleeding (from the aAmplatzer Cardiac Plug multicenter registry). Am J Cardiol  2017;120:414–20. PubMed

Gallo  F, Ronco  F, D’Amico  G, Della Rocca  DG, Mazzone  P, Bordignon  S, et al.  Clinical outcomes of left atrial appendage occlusion in patients with previous intracranial or gastrointestinal bleeding: insights from the LOGIC (left atrial appendage occlusion in patients with gastrointestinal or IntraCranial bleeding) international multicenter registry. Catheter Cardiovasc Interv  2023;101:1144–53. PubMed

Senzolo  M, Garcia-Pagan  JC. A major research gap: the use of anticoagulants in cirrhosis. J Hepatol  2023;79:1566–70. PubMed

Chokesuwattanaskul  R, Thongprayoon  C, Bathini  T, O’Corragain  OA, Sharma  K, Preechawat  S, et al.  Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: a meta-analysis. Eur J Gastroenterol Hepatol  2019;31:514–9. PubMed

Simon  TG, Schneeweiss  S, Singer  DE, Sreedhara  SK, Lin  KJ. Prescribing trends of oral anticoagulants in US patients with cirrhosis and nonvalvular atrial fibrillation. J Am Heart Assoc  2023;12:e026863. PubMed PMC

Senzolo  M, Garcia-Tsao  G, García-Pagán  JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol  2021;75:442–53. PubMed

Lee  SR, Lee  HJ, Choi  EK, Han  KD, Jung  JH, Cha  MJ, et al.  Direct oral anticoagulants in patients with atrial fibrillation and liver disease. J Am Coll Cardiol  2019;73:3295–308. PubMed

Mir  T, Rawasia  WF, Uddin  M, Sheikh  M, Munir  MB, Balla  S. Left atrial appendage closure device outcomes among cirrhosis patients with atrial fibrillation: a United States national cohort study. Europace  2023;25:1408–14. PubMed PMC

Calvert  P, Gupta  D. Left atrial appendage occlusion in patients with cirrhotic liver disease: the importance of patient selection. Europace  2023;25:1315–7. PubMed PMC

Schreuder  F, van Nieuwenhuizen  KM, Hofmeijer  J, Vermeer  SE, Kerkhoff  H, Zock  E, et al.  Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in The Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurol  2021;20:907–16. PubMed

SoSTART Collaboration . Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol  2021;20:842–53. PubMed

Population Health Research Institute . NOACs for stroke prevention in patients with atrial fibrillation and previous ICH. 2019. https://classic.clinicaltrials.gov/show/NCT02998905 (8 February 2024, date last assessed).

Liu  X, Guo  S, Xu  Z. Meta-Analysis of oral anticoagulants and adverse outcomes in atrial fibrillation patients after intracranial hemorrhage. Front Cardiovasc Med  2022;9:961000. PubMed PMC

Cochrane  A, Chen  C, Stephen  J, Rønning  OM, Anderson  CS, Hankey  GJ, et al.  Antithrombotic treatment after stroke due to intracerebral haemorrhage. Cochrane Database Syst Rev  2023;1:CD012144. PubMed PMC

Ivany  E, Lane  DA, Dan  GA, Doehner  W, Farkowski  MM, Iliodromitis  K, et al.  Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey. Europace  2021;23:806–14. PubMed

Population Health Research Institute . EdoxabaN foR IntraCranial Hemorrhage survivors with atrial fibrillation (ENRICH-AF). 2019. https://classic.clinicaltrials.gov/show/NCT03950076 (8 February 2024, date last accessed).

Imperial College London Wuerzburg University Hospital Julius-Maximilians University Medical University of Graz University of Liverpool King’s College London, et al. PREvention of STroke in Intracerebral haemorrhaGE survivors with atrial fibrillation. 2019. https://classic.clinicaltrials.gov/show/NCT03996772 (8 February 2024, date last accessed).

University Hospital Lille, Ministry of Health France, Institut National de la Santé Et de la Recherche Médicale France . Avoiding anticoagulation after intracerebral haemorrhage. 2019. https://classic.clinicaltrials.gov/show/NCT03243175 (8 February 2024, date last accsessed).

Oslo University Hospital . Study of antithrombotic treatment after intracerebral haemorrhage. 2018. https://classic.clinicaltrials.gov/show/NCT03186729 (8 February 2024, date last accessed).

Yale University, National Institute of Neurological Disorders and Stroke . Anticoagulation in ICH survivors for stroke prevention and recovery. 2022. https://classic.clinicaltrials.gov/show/NCT03907046  (8 February 2024, date last accessed).

January  CT, Wann  LS, Calkins  H, Chen  LY, Cigarroa  JE, Cleveland  JC  Jr, et al.  2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation  2019;140:e125–51. PubMed

Steffel  J, Collins  R, Antz  M, Cornu  P, Desteghe  L, Haeusler  KG, et al.  2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace  2021;23:1612–76. PubMed

National Institute of Cardiology Warsaw Poland, Medical Research Agency Poland . Optimal antiplatelet therapy following left atrial appendage closure in dialyzed patients. 2022. https://classic.clinicaltrials.gov/show/NCT05660811 (8 February 2024, date last accessed).

Garg  J, Shah  S, Shah  K, Bhardwaj  R, Contractor  T, Mandapati  R, et al.  Left atrial appendage closure in patients with intracranial hemorrhage. J Interv Card Electrophysiol  2022;64:551–6. PubMed

Haeusler  KG, Tütüncü  S, Kunze  C, Schurig  J, Malsch  C, Harder  J, et al.  Oral anticoagulation in patients with atrial fibrillation and acute ischaemic stroke: design and baseline data of the prospective multicentre Berlin Atrial Fibrillation Registry. Europace  2019;21:1621–32. PubMed

Tütüncü  S, Olma  M, Kunze  C, Dietzel  J, Schurig  J, Fiessler  C, et al.  Off-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: results of the prospective multicenter Berlin Atrial Fibrillation Registry. J Neurol  2022;269:470–80. PubMed PMC

Polymeris  AA, Meinel  TR, Oehler  H, Hölscher  K, Zietz  A, Scheitz  JF, et al.  Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. J Neurol Neurosurg Psychiatry  2022;93:588–98. PubMed PMC

Benz  AP, Hohnloser  SH, Eikelboom  JW, Carnicelli  AP, Giugliano  RP, Granger  CB, et al.  Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. Eur Heart J  2023;44:1807–14. PubMed PMC

Paciaroni  M, Caso  V, Agnelli  G, Mosconi  MG, Giustozzi  M, Seiffge  DJ, et al.  Recurrent ischemic stroke and bleeding in patients with atrial fibrillation who suffered an acute stroke while on treatment with nonvitamin K antagonist oral anticoagulants: the RENO-EXTEND study. Stroke  2022;53:2620–7. PubMed

Seiffge  DJ, De Marchis  GM, Koga  M, Paciaroni  M, Wilson  D, Cappellari  M, et al.  Ischemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. Ann Neurol  2020;87:677–87. PubMed PMC

Karl Georg  H. Ischaemic stroke in atrial fibrillation patients while on oral anticoagulation-a call for A-C-T-I-O-N. Eur Heart J  2023;44:1815–7. PubMed

Maarse  M, Seiffge  D, Fierro  N, Tondo  C, Pracon  R, De Backer  O, et al.  Left atrial appendage occlusion versus standard of care in patients with atrial fibrillation and a prior thrombo-embolic event despite oral anticoagulant therapy: a propensity score matched comparison. Eur Heart J  2022;43:ehac544.632.

Hamilton Health Sciences Corporation, McMaster University, Population Health Research Institute, Boston Scientific Corporation . The fourth left atrial appendage occlusion study. 2023. https://classic.clinicaltrials.gov/show/NCT05963698 (8 February 2024, date last accessed).

Insel Gruppe AG University Hospital Bern . Early closure of left atrial appendage for patients with atrial fibrillation and ischemic stroke despite anticoagulation therapy. 2024. https://classic.clinicaltrials.gov/show/NCT05976685 (8 February 2024, date last accessed).

Jensen  M, Suling  A, Metzner  A, Schnabel  RB, Borof  K, Goette  A, et al.  Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial. Lancet Neurol  2023;22:45–54. PubMed

Nippon Medical School, Daiichi Sankyo Co. Ltd . STroke secondary prevention with catheter ABLation and EDoxaban for patients with non-valvular atrial fibrillation: STABLED study. 2018. https://classic.clinicaltrials.gov/show/NCT03777631 (8 February 2024, date last accessed).

De Potter  T, Yodfat  O, Shinar  G, Neta  A, Reddy  VY, Neuzil  P, et al.  Permanent bilateral carotid filters for stroke prevention in atrial fibrillation. Curr Cardiol Rep  2020;22:144. PubMed PMC

Javelin Medical, Population Health Research Institute . Carotid implants for PreveNtion of STrokE ReCurrEnce from large vessel occlusion in atrial fibrillation patients treated with oral anticoagulation. 2023. https://classic.clinicaltrials.gov/show/NCT05723926 (8 February 2024, date last accessed).

Blackshear  JL, Odell  JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg  1996;61:755–9. PubMed

Stoddard  MF, Singh  P, Dawn  B, Longaker  RA. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Am Heart J  2003;145:676–82. PubMed

Zhan  Y, Joza  J, Al Rawahi  M, Barbosa  RS, Samuel  M, Bernier  M, et al.  Assessment and management of the left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Can J Cardiol  2018;34:252–61. PubMed

Lurie  A, Wang  J, Hinnegan  KJ, McIntyre  WF, Belley-Côté  EP, Amit  G, et al.  Prevalence of left atrial thrombus in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol  2021;77:2875–86. PubMed

Steffel  J, Heidbüchel  H. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: comment—authors’ reply. Europace  2021;23:1685–6. PubMed

Kolakowski  K, Farkowski  MM, Pytkowski  M, Gardziejczyk  P, Kowalik  I, Dąbrowski  R, et al.  The comparative effectiveness and safety of different anticoagulation strategies for treatment of left atrial appendage thrombus in the setting of chronic anticoagulation for atrial fibrillation or flutter. Cardiovasc Drugs Ther  2023;37:159–68. PubMed PMC

Boccuzzi  GG, Montabone  A, D’Ascenzo  F, Colombo  F, Ugo  F, Muraglia  S, et al.  Cerebral protection in left atrial appendage closure in the presence of appendage thrombosis. Catheter Cardiovasc Interv  2021;97:511–5. PubMed

Fink  T, Ouyang  F, Heeger  CH, Sciacca  V, Reissmann  B, Keelani  A, et al.  Management of thrombus formation after electrical isolation of the left atrial appendage in patients with atrial fibrillation. Europace  2020;22:1358–66. PubMed

Popescu  SS, Heeger  CH, Keelani  A, Tilz  RR. Percutaneous left atrial appendage closure with the LAmbre device protected by a cerebral protection system in a 76-year-old man with persistent left atrial appendage thrombus. Am J Case Rep  2022;23:e937063. PubMed PMC

Mohandes  M, Moreno  C, Guillén  M, Anmad Shihadeh  L, Zambrano  D. Percutaneous left atrial appendage closure containing thrombus. Cardiol J  2022;29:884–5. PubMed PMC

Kozek-Langenecker  SA, Ahmed  AB, Afshari  A, Albaladejo  P, Aldecoa  C, Barauskas  G, et al.  Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016. Eur J Anaesthesiol  2017;34:332–95. PubMed

Saran  R, Robinson  B, Abbott  KC, Agodoa  LYC, Bragg-Gresham  J, Balkrishnan  R, et al.  US renal data system 2018 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis  2019;73:A7–8. PubMed PMC

Buiten  MS, de Bie  MK, Rotmans  JI, Gabreëls  BA, van Dorp  W, Wolterbeek  R, et al.  The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Heart  2014;100:685–90. PubMed

Vincenti  A, Passini  E, Fabbrini  P, Luise  MC, Severi  S, Genovesi  S. Recurrent intradialytic paroxysmal atrial fibrillation: hypotheses on onset mechanisms based on clinical data and computational analysis. Europace  2014;16:396–404. PubMed

Ng  KP, Edwards  NC, Lip  GY, Townend  JN, Ferro  CJ. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. Am J Kidney Dis  2013;62:615–32. PubMed

Carrero  JJ, Trevisan  M, Sood  MM, Bárány  P, Xu  H, Evans  M, et al.  Incident atrial fibrillation and the risk of stroke in adults with chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project. Clin J Am Soc Nephrol  2018;13:1314–20. PubMed PMC

Genovesi  S, Vincenti  A, Rossi  E, Pogliani  D, Acquistapace  I, Stella  A, et al.  Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis  2008;51:255–62. PubMed

Dahal  K, Kunwar  S, Rijal  J, Schulman  P, Lee  J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest  2016;149:951–9. PubMed

Szummer  K, Gasparini  A, Eliasson  S, Ärnlöv  J, Qureshi  AR, Bárány  P, et al.  Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc  2017;6:e004925. PubMed PMC

Rebora  P, Moia  M, Carpenedo  M, Valsecchi  MG, Genovesi  S. Best quality indicator of vitamin K antagonist therapy to predict mortality and bleeding in haemodialysis patients with atrial fibrillation. Blood Transfus  2021;19:487–94. PubMed PMC

Weijs  B, Blaauw  Y, Rennenberg  RJ, Schurgers  LJ, Timmermans  CC, Pison  L, et al.  Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J  2011;32:2555–62. PubMed

Connolly  SJ, Ezekowitz  MD, Yusuf  S, Eikelboom  J, Oldgren  J, Parekh  A, et al.  Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med  2009;361:1139–51. PubMed

Patel  MR, Mahaffey  KW, Garg  J, Pan  G, Singer  DE, Hacke  W, et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med  2011;365:883–91. PubMed

Granger  CB, Alexander  JH, McMurray  JJ, Lopes  RD, Hylek  EM, Hanna  M, et al.  Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med  2011;365:981–92. PubMed

Giugliano  RP, Ruff  CT, Braunwald  E, Murphy  SA, Wiviott  SD, Halperin  JL, et al.  Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med  2013;369:2093–104. PubMed

Kuno  T, Takagi  H, Ando  T, Sugiyama  T, Miyashita  S, Valentin  N, et al.  Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J Am Coll Cardiol  2020;75:273–85. PubMed

Su  X, Yan  B, Wang  L, Lv  J, Cheng  H, Chen  Y. Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis. Am J Kidney Dis  2021;78:678–89.e1. PubMed

Turakhia  MP, Blankestijn  PJ, Carrero  JJ, Clase  CM, Deo  R, Herzog  CA, et al.  Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Eur Heart J  2018;39:2314–25. PubMed PMC

Genovesi  S, Rebora  P, Gallieni  M, Stella  A, Badiali  F, Conte  F, et al.  Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study. J Nephrol  2017;30:573–81. PubMed

Kefer  J, Tzikas  A, Freixa  X, Shakir  S, Gafoor  S, Nielsen-Kudsk  JE, et al.  Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Int J Cardiol  2016;207:335–40. PubMed

Fink  T, Paitazoglou  C, Bergmann  MW, Sano  M, Keelani  A, Sciacca  V, et al.  Left atrial appendage closure in end-stage renal disease and hemodialysis: data from a German multicenter registry. Catheter Cardiovasc Interv  2023;101:610–9. PubMed

Munir  MB, Khan  MZ, Darden  D, Nishimura  M, Vanam  S, Pasupula  DK, et al.  Association of chronic kidney disease and end-stage renal disease with procedural complications and in-hospital outcomes from left atrial appendage occlusion device implantation in patients with atrial fibrillation: insights from the national inpatient sample of 36,065 procedures. Heart Rhythm O2  2021;2:472–9. PubMed PMC

Fastner  C, Brachmann  J, Lewalter  T, Zeymer  U, Sievert  H, Borggrefe  M, et al.  Left atrial appendage closure in patients with chronic kidney disease: results from the German multicentre LAARGE registry. Clin Res Cardiol  2021;110:12–20. PubMed PMC

Luani  B, Genz  C, Herold  J, Mitrasch  A, Mitusch  J, Wiemer  M, et al.  Cerebrovascular events, bleeding complications and device related thrombi in atrial fibrillation patients with chronic kidney disease and left atrial appendage closure with the WATCHMAN device. BMC Cardiovasc Disord  2019;19:112. PubMed PMC

Al Ali  R, Vukadinović  D, Maziak  W, Katmeh  L, Schwarz  V, Mahfoud  F, et al.  Cardiovascular effects of waterpipe smoking: a systematic review and meta-analysis. Rev Cardiovasc Med  2020;21:453–68. PubMed

Fundación EPIC . Left atrial appendage occlusion with WATCHMAN® device in patients with non-valvular atrial fibrillation and end-stage chronic kidney disease on hemodialysis. 2018. https://classic.clinicaltrials.gov/show/NCT03446794 (8 February 2024, date last accessed).

University of Magdeburg . Left atrial appendage occlusion vs. usual care in patients with atrial fibrillation and severe chronic kidney disease. 2014. https://classic.clinicaltrials.gov/show/NCT02039167 (8 February 2024, date last accessed).

Population Health Research Institute . The Strategy to Prevent Hemorrhage Associated with Anticoagulation in Renal Disease Management (STOP HARM) trial. 2016. https://classic.clinicaltrials.gov/show/NCT02885545 (8 February 2024, date last accessed).

Vallurupalli  S, Sharma  T, Al’Aref  S, Devabhaktuni  SR, Dhar  G. Left atrial appendage closure: an alternative to anticoagulation for stroke prevention in patients with kidney disease. Kidney360  2022;3:396–402. PubMed PMC

Genovesi  S, Porcu  L, Rebora  P, Slaviero  G, Casu  G, Bertoli  S, et al.  Long term safety and efficacy of left atrial appendage occlusion in dialysis patients with atrial fibrillation: a multi-center, prospective, open label, observational study. Clin Kidney J  2023;16:2683–1692. PubMed PMC

de Groot  JR, Weiss  TW, Kelly  P, Monteiro  P, Deharo  JC, de Asmundis  C, et al.  Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. Eur Heart J Cardiovasc Pharmacother  2021;7:f30–9. PubMed PMC

Kornej  J, Henger  S, Seewöster  T, Teren  A, Burkhardt  R, Thiele  H, et al.  Prevalence of atrial fibrillation dependent on coronary artery status: insights from the LIFE-Heart study. Clin Cardiol  2020;43:1616–23. PubMed PMC

Camen  S, Csengeri  D, Geelhoed  B, Niiranen  T, Gianfagna  F, Vishram-Nielsen  JK, et al.  Risk factors, subsequent disease onset, and prognostic impact of myocardial infarction and atrial fibrillation. J Am Heart Assoc  2022;11:e024299. PubMed PMC

Cannon  CP, Bhatt  DL, Oldgren  J, Lip  GYH, Ellis  SG, Kimura  T, et al.  Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med  2017;377:1513–24. PubMed

Lopes  RD, Heizer  G, Aronson  R, Vora  AN, Massaro  T, Mehran  R, et al.  Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med  2019;380:1509–24. PubMed

Vranckx  P, Valgimigli  M, Eckardt  L, Tijssen  J, Lewalter  T, Gargiulo  G, et al.  Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet  2019;394:1335–43. PubMed

Gibson  CM, Mehran  R, Bode  C, Halperin  J, Verheugt  FW, Wildgoose  P, et al.  Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med  2016;375:2423–34. PubMed

Gargiulo  G, Goette  A, Tijssen  J, Eckardt  L, Lewalter  T, Vranckx  P, et al.  Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J  2019;40:3757–67. PubMed

Potpara  TS, Mujovic  N, Proietti  M, Dagres  N, Hindricks  G, Collet  JP, et al.  Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Europace  2020;22:33–46. PubMed

Alexander  JH, Wojdyla  D, Vora  AN, Thomas  L, Granger  CB, Goodman  SG, et al.  Risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS. Circulation  2020;141:1618–27. PubMed

Ancedy  Y, Lecoq  C, Saint Etienne  C, Ivanes  F, Angoulvant  D, Babuty  D, et al.  Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: what is the impact of guideline adherence?  Int J Cardiol  2016;203:987–94. PubMed

Windecker  S, Kolh  P, Alfonso  F, Collet  JP, Cremer  J, Falk  V, et al.  2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J  2014;35:2541–619. PubMed

Wang  Y, Wu  D, Ma  J, Liu  X, Zhang  H, So  CY, et al.  The feasibility and safety of “one-stop” left atrial appendage closure and percutaneous coronary intervention in atrial fibrillation patients with significant coronary artery disease (PCI-LAAC study). Am J Cardiovasc Dis  2021;11:679–87. PubMed PMC

Losik  D, Romanov  A, Grazhdankin  I, Shabanov  V, Ponomarev  D, Mikheenko  I, et al.  Feasibility of concomitant left atrial appendage closure and percutaneous coronary intervention in patients with acute coronary syndrome and atrial fibrillation: a randomized pilot study. Heart Vessels  2023;38:881–8. PubMed

Meshalkin Research Institute of Pathology of Circulation, Boston Scientific Corporation . Left atrial appendage closure compared to standard antiplatelet therapy in patients with AF who underwent PCI. 2015. https://classic.clinicaltrials.gov/show/NCT02492230 (8 February 2024, date last accessed).

Yonsei University . Safety and efficacy of left atrial appendage closure versus antithrombotic therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation due to complex coronary artery disease. 2016. https://classic.clinicaltrials.gov/show/NCT02606552 (8 February 2024, date last accessed).

Noseworthy  PA, Yao  X, Deshmukh  AJ, Van Houten  H, Sangaralingham  LR, Siontis  KC, et al.  Patterns of anticoagulation use and cardioembolic risk after catheter ablation for atrial fibrillation. J Am Heart Assoc  2015;4:e002597. PubMed PMC

Wintgens  L, Romanov  A, Phillips  K, Ballesteros  G, Swaans  M, Folkeringa  R, et al.  Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry. Europace  2018;20:1783–9. PubMed

Pasupula  DK, Siddappa Malleshappa  SK, Munir  MB, Bhat  AG, Anandaraj  A, Jakkoju  A, et al.  Combined atrial fibrillation ablation and left atrial appendage occlusion procedure in the United States: a propensity score matched analysis from 2016–2019 national readmission database. Europace  2023;25:390–9. PubMed PMC

Romanov  A, Pokushalov  E, Artemenko  S, Yakubov  A, Stenin  I, Kretov  E, et al.  Does left atrial appendage closure improve the success of pulmonary vein isolation? Results of a randomized clinical trial. J Interv Card Electrophysiol  2015;44:9–16. PubMed

Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research, Bayer, Biotronik Canada Inc . Optimal anticoagulation for higher risk patients post-catheter ablation for atrial fibrillation trial. 2016. https://classic.clinicaltrials.gov/show/NCT02168829 (8 February 2024, date last accessed).

Phillips  KP, Walker  DT, Humphries  JA. Combined catheter ablation for atrial fibrillation and Watchman(R) left atrial appendage occlusion procedures: five-year experience. J Arrhythm  2016;32:119–26. PubMed PMC

Wilber  DJ. PowerPoint presentation (acc.org). 2021. https://www.acc.org/education-and-meetings/image-and-slide-gallery/~/media/B4DF9BAC740A46198403DBE12AB7E193.pdf (8 February 2024, date last accessed).

Nishimura  M, Lupercio-Lopez  F, Hsu  JC. Left atrial appendage electrical isolation as a target in atrial fibrillation. JACC Clin Electrophysiol  2019;5:407–16. PubMed

Rillig  A, Tilz  RR, Lin  T, Fink  T, Heeger  CH, Arya  A, et al.  Unexpectedly high incidence of stroke and left atrial appendage thrombus formation after electrical isolation of the left atrial appendage for the treatment of atrial tachyarrhythmias. Circ Arrhythm Electrophysiol  2016;9:e003461. PubMed

Panikker  S, Jarman  JW, Virmani  R, Kutys  R, Haldar  S, Lim  E, et al.  Left atrial appendage electrical isolation and concomitant device occlusion to treat persistent atrial fibrillation: a first-in-human safety, feasibility, and efficacy study. Circ Arrhythm Electrophysiol  2016;9:e003710. PubMed

Smith  CR, Leon  MB, Mack  MJ, Miller  DC, Moses  JW, Svensson  LG, et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med  2011;364:2187–98. PubMed

Adams  DH, Popma  JJ, Reardon  MJ. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med  2014;371:967–8. PubMed

Attinger-Toller  A, Maisano  F, Senn  O, Taramasso  M, Shakir  S, Possner  M, et al.  “One-Stop shop”: safety of combining transcatheter aortic valve replacement and left atrial appendage occlusion. JACC Cardiovasc Interv  2016;9:1487–95. PubMed

Drosos  I, De Rosa  R, Cremer  S, Seppelt  PC, Hemmann  K, Oppermann  J, et al.  Percutaneous left atrial appendage occlusion in a frail, high-risk, octogenarian patient population, after having undergone transcatheter aortic valve implantation. BMC Cardiovasc Disord  2022;22:349. PubMed PMC

D’Amico  G, Estevez-Loureiro  R, Rofastes  XF, Ronco  F, Nombela-Franco  L, Melica  B, et al.  Combined procedure of percutaneous mitral valve repair and left atrial appendage occlusion: a multicenter study. JACC Cardiovasc Interv  2021;14:590–2. PubMed

Kleinecke  C, Buffle  E, Link  J, Häner  J, Sedaghat  A, Galea  R, et al.  Amplatzer left atrial appendage closure: single versus combined procedures. Catheter Cardiovasc Interv  2021;97:E973–81. PubMed

Kuwata  S, Taramasso  M, Zuber  M, Suetsch  G, Attinger-Toller  A, Wicki  D, et al.  Feasibility of concomitant MitraClip and left atrial appendage occlusion. EuroIntervention  2017;12:1940–5. PubMed

Lane  CE, Eleid  MF, Holmes  DR  Jr. An under-recognized high-risk atrial fibrillation population: analyzing transcatheter mitral valve repair patients for left atrial appendage closure device application. Catheter Cardiovasc Interv  2019;94:274–9. PubMed

Arellano-Serrano  C, Monivas  V, Estevez-Loureiro  R. Combined percutaneous treatment of severe triscuspid regurgitation and left atrial appendage closure. J Invasive Cardiol  2019;31:E4–5. PubMed

Belli  M, Zanin  F, Macrini  M, Barone  L, Marchei  M, Muscoli  S, et al.  Combined MitraClip and left atrial appendage occlusion: is it still a Utopia?  Front Cardiovasc Med  2022;9:940560. PubMed PMC

Kuwata  S, Vierecke  J, Gloekler  S, Maisano  F, Meier  B, Nietlispach  F. Left atrial appendage closure for “primary primary” prevention during percutaneous closure of septal defects in patients with large atria but no atrial fibrillation. Cardiol J  2018;25:179–87. PubMed

Song  Y, Xing  H, Koch  PD, Li  X, Zhang  Y. The feasibility and safety of combining atrial septal defect/patent foramen ovale and left atrial appendage closure: a systematic review and meta-analysis. Front Cardiovasc Med  2022;9:1080257. PubMed PMC

Tzikas  A, Samaras  A, Kartas  A, Vasdeki  D, Fotos  G, Dividis  G, et al.  Motivational Interviewing to Support Oral AntiCoagulation adherence in patients with non-valvular Atrial Fibrillation (MISOAC-AF): a randomized clinical trial. Eur Heart J Cardiovasc Pharmacother  2021;7:f63–71. PubMed

Martinez  C, Katholing  A, Wallenhorst  C, Freedman  SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost  2016;115:31–9. PubMed

Ozaki  AF, Choi  AS, Le  QT, Ko  DT, Han  JK, Park  SS, et al.  Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes  2020;13:e005969. PubMed

Chen  S, Weise  FK, Chun  KRJ, Schmidt  B. Antithrombotic strategies after interventional left atrial appendage closure: an update. Expert Rev Cardiovasc Ther  2018;16:675–8. PubMed

Branca  L, Tomasoni  D, Cimino  G, Cersosimo  A, Lombardi  CM, Chizzola  G, et al.  Impact and predictors of device-related thrombus after percutaneous left atrial appendage closure. J Cardiovasc Med (Hagerstown)  2023;24:12–9. PubMed

Active Writing Group of the ACTIVE Investigators, Connolly  S, Pogue  J, Hart  R, Pfeffer  M, Hohnloser  S, et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet  2006;367:1903–12. PubMed

Connolly  SJ, Eikelboom  J, Joyner  C, Diener  HC, Hart  R, Golitsyn  S, et al.  Apixaban in patients with atrial fibrillation. N Engl J Med  2011;364:806–17. PubMed

Mant  J, Hobbs  FD, Fletcher  K, Roalfe  A, Fitzmaurice  D, Lip  GY, et al.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the aged study, BAFTA): a randomised controlled trial. Lancet  2007;370:493–503. PubMed

Okumura  K, Akao  M, Yoshida  T, Kawata  M, Okazaki  O, Akashi  S, et al.  Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med  2020;383:1735–45. PubMed

Riegler  L, Palermi  S, Scarafile  R, Gioia  R, Pastore  F, Lombardi  A, et al.  Clinical and multi-modality imaging approach in the selection of patients for left atrial appendage closure. Rev Cardiovasc Med  2021;22:1197–204. PubMed

Cruz-González  I, Trejo-Velasco  B. Percutaneous left atrial appendage occlusion in the current practice. Kardiol Pol  2021;79:255–68. PubMed

Ledwoch  J, Sievert  K, Boersma  LVA, Bergmann  MW, Ince  H, Kische  S, et al.  Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN. Europace  2020;22:1036–43. PubMed

Freeman  JV, Higgins  AY, Wang  Y, Du  C, Friedman  DJ, Daimee  UA, et al.  Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation. J Am Coll Cardiol  2022;79:1785–98. PubMed PMC

Freeman  J, Hsu  JC, Kapadia  S, Yeh  R, Price  M, Nair  DG, et al.  Ce-452771-4 outcomes with different postprocedural antithrombotic therapy regimens following left atrial appendage occlusion. Heart Rhythm  2023;20:S36–7.

Carvalho  PEP, Gewehr  DM, Miyawaki  IA, Nogueira  A, Felix  N, Garot  P, et al.  Comparison of initial antithrombotic regimens after left atrial appendage occlusion: a systematic review and network meta-analysis. J Am Coll Cardiol  2023;82:1765–73. PubMed

Mhanna  M, Beran  A, Al-Abdouh  A, Jabri  A, Al-Aaraj  A, Sajdeya  O, et al.  Single versus dual antiplatelet therapy following left atrial appendage occlusion in patients with high bleeding risk. Curr Probl Cardiol  2022;47:101269. PubMed

Vignali  L, Gurgoglione  FL, Barocelli  F, Cattabiani  MA, Solinas  E, Maini  A, et al.  Looking for optimal antithrombotic strategy after transcatheter left atrial appendage occlusion: a real-world comparison of different antiplatelet regimens. Int J Cardiol  2023;371:92–9. PubMed

Rodriguez-Gabella  T, Nombela-Franco  L, Regueiro  A, Jiménez-Quevedo  P, Champagne  J, O’Hara  G, et al.  Single antiplatelet therapy following left atrial appendage closure in patients with contraindication to anticoagulation. J Am Coll Cardiol  2016;68:1920–1. PubMed

Azienda Ospedaliero Universitaria Maggiore della Carita, Abbott Medical Devices . Head-to-head comparison of single versus dual antiplatelet treatment strategy after percutaneous left atrial appendage closure: a multicenter, randomized study. 2021. https://classic.clinicaltrials.gov/show/NCT05554822 (8 February 2024, date last accessed).

Cepas-Guillen  PL, Flores-Umanzor  E, Regueiro  A, Brugaletta  S, Ibañez  C, Sanchis  L, et al.  Low dose of direct oral anticoagulants after left atrial appendage occlusion. J Cardiovasc Dev Dis  2021;8:142. PubMed PMC

Della Rocca  DG, Magnocavallo  M, Di Biase  L, Mohanty  S, Trivedi  C, Tarantino  N, et al.  Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion. JACC Cardiovasc Interv  2021;14:2353–64. PubMed

Freixa  X. Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA). 2019. https://classic.clinicaltrials.gov/show/NCT05632445 (8 February 2024, date last accessed).

Freixa  X, Cruz-González  I, Cepas-Guillén  P, Millan  X, Flores-Umanzor  E, Asmarats  L, et al. A39887XF. Low dose direct oral anticoagulation vs. DAPT after LAAO EuroPCR. 2023. https://eposter.europa-organisation.com/2023/europcr/index/slide/abstract/620 (8 February 2024, date last accessed).

Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Institut universitaire de cardiologie et de pneumologie de Québec University Laval . Short-term anticoagulation versus antiplatelet therapy for preventing device thrombosis following left atrial appendage closure. 2018. https://classic.clinicaltrials.gov/show/NCT03568890 (8 February 2024, date last accessed).

Sondergaard  L, Wong  YH, Reddy  VY, Boersma  LVA, Bergmann  MW, Doshi  S, et al.  Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN. JACC Cardiovasc Interv  2019;12:1055–63. PubMed

Schmidt  B, Nielsen-Kudsk  JE, Ellis  CR, Thaler  D, Sabir  SA, Gambhir  A, et al.  Incidence, predictors, and clinical outcomes of device-related thrombus in the Amulet IDE trial. JACC Clin Electrophysiol  2023;9:96–107. PubMed

Dukkipati  SR, Kar  S, Holmes  DR, Doshi  SK, Swarup  V, Gibson  DN, et al.  Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation  2018;138:874–85. PubMed

Dukkipati  SR, Holmes  DR  Jr, Doshi  SK, Kar  S, Singh  SM, Gibson  D, et al.  Impact of peridevice leak on 5-year outcomes after left atrial appendage closure. J Am Coll Cardiol  2022;80:469–83. PubMed

Alkhouli  M, Du  C, Killu  A, Simard  T, Noseworthy  PA, Friedman  PA, et al.  Clinical impact of residual leaks following left atrial appendage occlusion: insights from the NCDR LAAO registry. JACC Clin Electrophysiol  2022;8:766–78. PubMed PMC

Sharma  SP, Turagam  MK, Gopinathannair  R, Reddy  V, Kar  S, Mohanty  S, et al.  Direct current cardioversion of atrial fibrillation in patients with left atrial appendage occlusion devices. J Am Coll Cardiol  2019;74:2267–74. PubMed

Maarse  M, Wintgens  LIS, Ponomarenko  A, Phillips  KP, Romanov  AB, Ballesteros  G, et al.  Impact of anticoagulation strategy after left atrial appendage occlusion in patients requiring direct current cardioversion. J Cardiovasc Electrophysiol  2021;32:737–44. PubMed